Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings: a Prospective Cohort Study in South Sudan and DRC
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 592
- 试验地点
- 3
- 主要终点
- Hospitalization
研究概览
简要总结
This study will characterize risk factors for poor COVID-19 outcomes (hospitalization, death) and clinical progression of hospitalized COVID-19 patients in South Sudan and Eastern Democratic Republic of the Congo.
详细描述
A prospective cohort design will be used to follow suspected, probable, and confirmed COVID-19 cases presenting for care at International Medical Corp [supported] health facilities in Juba, South Sudan and the Kivus in Eastern Democratic Republic of the Congo (DRC). This research seeks to assess risk factors for poor outcomes and characterize clinical disease progression of COVID-19 cases in resource-poor humanitarian contexts in Africa. Specifically, this study aims to characterize risk factors for poor COVID-19 outcomes, including both co-morbidities with evidence from high income settings, as well as prevalent conditions in humanitarian settings (e.g., acute malnutrition, malaria, HIV) for which data is not yet available. This research also aims to determine how the progression of confirmed COVID-19 cases in resource-poor African settings may differ from other settings where data are available.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 5 Years 至 —(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Suspected, probable, and confirmed COVID-19 cases presenting for care at participating health facilities (either by walk-in, referral or transfer) or identified by mobile contact tracing teams.
排除标准
- •Individuals unable or unwilling to give informed consent (e.g., due to mental impairment)
结局指标
主要结局
Hospitalization
时间窗: patients will be followed until asymptomatic or deceased (an average of approximately 1 month)
Hospitalization due to COVID-19 (proportion of participants hospitalized and risk factors for hospitalization)
Mortality
时间窗: patients will be followed until asymptomatic or deceased (an average of approximately 1 month)
Death due to COVID-19 (proportion of participants deceased and risk factors for death)
次要结局
未报告次要终点
